NeuroSense to File New Drug Submission for PrimeC in ALS with Health Canada After Positive Pre-NDS Meeting
NRSN is trading near its 52-week low of $0.63 (9.7% above the low).
Summary
NeuroSense plans to file a New Drug Submission for PrimeC in ALS with Health Canada after a positive pre-submission meeting, supported by new survival data showing a 14.9-month median benefit.
Key Events · Product Development and Regulatory · NRSN
-
NDS Filing Planned for PrimeC in ALS
Following a constructive Pre-NDS meeting, NeuroSense intends to file a New Drug Submission to Health Canada for PrimeC in ALS, with the submission expected in the coming months.
-
Survival Benefit Data Strengthens Package
The planned NDS will include new PARADIGM data showing a 14.9-month median survival benefit (HR 0.35, p=0.0037) and consistent biomarker effects, significantly bolstering the regulatory case.
-
Regulatory Momentum Builds on Recent Clinical Wins
This update follows positive Phase 2b biomarker and efficacy results announced in June 2026, and aligns with recent insider purchases by the CEO and CFO totaling $400,000.
-
Next Milestone: NDS Completion
NeuroSense expects to complete and file the NDS in the coming months, with further updates anticipated as the submission advances.
Analysis · NRSN · Life Sciences
NeuroSense is advancing its lead ALS drug, PrimeC, toward a New Drug Submission in Canada following a constructive meeting with Health Canada. The submission will include new survival data from the Phase 2b PARADIGM study showing a 14.9-month median survival benefit (HR 0.35, p=0.0037), significantly strengthening the case for approval. This marks a major regulatory milestone for a company with a market cap under $25 million, where a successful NDS could transform the investment thesis. The news comes on the heels of positive Phase 2b biomarker and efficacy data announced in June, and insider buying by the CEO and CFO totaling $400,000, signaling management confidence in the regulatory path.
At the time of this filing, NRSN was trading at $0.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.7M. The 52-week trading range was $0.63 to $2.10. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.